For Providers
A New Era in Ovarian Cancer Detection and Women’s Health
Finally, ovarian cancer can be found early—making it possible to take control of health when every moment counts.
Evident offers a new way forward, enabling women and their physicians to identify ovarian cancer earlier—creating an opportunity to intervene sooner, explore broader treatment options, and pursue better outcomes. Evident marks the beginning of a new chapter in women’s health, where early detection becomes an attainable reality.
Why Early Detection Matters
Physicians have lacked dependable tools to screen for ovarian cancer, left instead to wait for acute symptoms. Current tests are not sufficiently sensitive for detection of early disease, yielding results that can be inconclusive or misleading. This gap has forced clinicians to deliver diagnoses of advanced disease, limiting their options for patient management
Earlier detection remains the single greatest opportunity to improve survival.
A New Standard of Care
Evident fills a critical gap in gynecologic care, positioning physicians at the forefront of innovation in women’s health. Supported by rigorous evidence and developed with leading clinical experts, this powerful blood test provides unique clinical value. By providing early detection and distinguishing ovarian cancer from benign pelvic disease, Evident surpasses existing diagnostic modalities. Physicians gain greater clarity and can provide more informed guidance to their patients.
Evident has proven superiority to existing diagnostic methods—offering clarity and confidence where none existed before:
High sensitivity across all stages,
including early disease
High specificity
that minimizes unnecessary referrals and interventions
Performance validated
in rigorously designed, blinded preclinical cohorts
Test Performance
Evident analyzes tumor-associated extracellular vesicles (EVs) using immunoaffinity capture and multiplex proximity-ligation PCR. This enables detection of multiple biomarker signatures colocalized within the same EV—improving both sensitivity and specificity relative to serum analytes.
Key performance results from verification and validation studies show:
- 92–97% sensitivity across all ovarian cancer stages
- 89% sensitivity for stage I disease where detection matters most
- 93–97% specificity, including in benign and inflammatory conditions where CA-125 yields high false positives
Understanding Test Reports
A simple blood draw provides a binary result—signal detected or signal not detected—for a clearer path forward.
The Evident test report includes:
- Overall test result (Signal Detected/Signal Not Detected)
- Quantitative risk score derived from multivariate index modeling
- Interpretive guidance aligned with Evident’s intended use populations
- Potential next steps (e.g., imaging, referral, observation)
The result is intended to complement—not replace—clinical evaluation, ultrasound, and guideline-based management pathways.
Integrating into Your Practice
With Evident, you can rely on easy ordering, training, and integration with current workflow—bringing innovation and trust to your practice.
For screening with Evident:
- Order as part of an annual wellness visit
- Venipuncture sample collected through standard phlebotomy
- Results returned promptly for follow-up planning
Discover the benefits to your practice:
- Broaden screening offerings to your patients
- Clear testing protocol that fits into existing preventive care models
- High specificity reduces the burden often associated with CA-125–based assessments
Learn More About Offering the Test
The Evident™ Early Access Program is now open to select clinical partners. Stay tuned as Mercy Bio prepares for broader rollout.
Learn more about offering Evident in your practice.
Request clinical data, implementation details, and onboarding materials:
